Momenta Pharmaceuticals Inc. (MNTA) PT Set at $6.00 by Maxim Group
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) has been assigned a $6.00 price objective by Maxim Group in a research note issued to investors on Tuesday. The firm presently has a “sell” rating on the biotechnology company’s stock. Maxim Group’s target price suggests a potential downside of 57.60% from the stock’s previous close.
A number of other equities research analysts have also recently commented on MNTA. Zacks Investment Research cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 5th. JPMorgan Chase & Co. reduced their target price on shares of Momenta Pharmaceuticals from $21.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, August 5th. Aegis initiated coverage on shares of Momenta Pharmaceuticals in a research report on Tuesday, November 22nd. They issued a “hold” rating and a $15.00 target price for the company. Stifel Nicolaus set a $20.00 target price on shares of Momenta Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday. Finally, Barclays PLC upgraded shares of Momenta Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $13.00 to $19.00 in a research report on Tuesday, October 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $16.10.
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 14.15 on Tuesday. Momenta Pharmaceuticals has a 52-week low of $7.86 and a 52-week high of $18.26. The stock’s market capitalization is $975.74 million. The firm has a 50-day moving average of $12.43 and a 200 day moving average of $11.73.
Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. The business had revenue of $299.14 million for the quarter, compared to the consensus estimate of $25.68 million. Momenta Pharmaceuticals had a negative net margin of 93.75% and a negative return on equity of 26.55%. The company’s revenue was up 2067.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.44) earnings per share. Equities research analysts forecast that Momenta Pharmaceuticals will post ($1.16) EPS for the current fiscal year.
In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 5,880 shares of Momenta Pharmaceuticals stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $13.68, for a total transaction of $80,438.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.10% of the company’s stock.
Several large investors have recently made changes to their positions in MNTA. Pacad Investment Ltd. bought a new stake in shares of Momenta Pharmaceuticals during the second quarter worth $103,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Momenta Pharmaceuticals during the second quarter worth $109,000. Jane Street Group LLC bought a new stake in shares of Momenta Pharmaceuticals during the second quarter worth $109,000. Profund Advisors LLC bought a new stake in shares of Momenta Pharmaceuticals during the third quarter worth $121,000. Finally, Mason Street Advisors LLC bought a new stake in shares of Momenta Pharmaceuticals during the second quarter worth $134,000. Institutional investors and hedge funds own 84.86% of the company’s stock.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.